Basic Information



GTO ID GTC3995
Trial ID NCT02197169
Disease Brain Glioma
Altered gene E1A|RGD
Therapeutic/Target gene Therapeutic gene
TherapyDNA oncolytic virus
Treatment Ad5-Delta 24RGD|DNX-2401|tasadenoturev
PhasePhase1
Recruitment statusCompleted
TitleA Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)
Year2014
CountryUnited States
Company sponsorDNAtrix, Inc.
Other ID(s)2401BT-IFN-001
Vector information
Vectoradenovirus
ConstructAd5-Delta 24RGD
Vector typetumor-selective, replication-competent oncolytic adenovirus
Transgene/Inserted geneRGD-motif, which was engineered into the fiber H-loop, enabling the virus to use αvβ3 or αvβ5 integrins to enter cells.
Regulatory elementRGD-motif
Viral genome modification24-base-pair deletion in the E1A gene

Clinical Result

Cohort1: DNX-2401
Administration route intratumoral injection
Age Adult, Older_Adult
Cohort2: DNX-2401_Interferon-gamma
Administration route intratumoral injection
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph